BIOQUAL, Inc. (OTC Pink: BIOQ) ( www.bioqual.com ):
Three Months Ended | ||||||
| 2020 | 2019 |
| |||
|
|
|
| |||
Revenue | $ | 14,920,475 | $ | 10,067,876 |
| |
Income Before Income Tax | $ | 2,496,988 | $ | 1,874,483 |
| |
Net Income | $ | 1,766,588 | $ | 1,324,483 |
| |
Basic Earnings per Share |
|
|
|
|
| |
of Common Stock | $ | 1.98 | $ | 1.48 | ||
Diluted Earnings per Share |
|
|
|
|
| |
of Common Stock | $ | 1.98 | $ | 1.48 | ||
Weighted Average |
|
|
|
|
| |
Number of Shares Outstanding |
|
|
|
|
| |
For Basic Earnings Per Share |
| 893,416 |
| 893,416 | ||
Weighted Average |
|
|
|
|
| |
Number of Shares Outstanding |
|
|
|
|
| |
For Diluted Earnings Per Share |
| 894,030 |
| 893,648 |
For more detail related to the fiscal year 2021 unaudited first quarter results, please visit our web site at www.bioqual.com .
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201021005799/en/
Mark G. Lewis, Ph.D., CEO (240-404-7654)